ASCO: Merck's Keytruda targets Pfizer's shaky Sutent post-surgery use in kidney cancer

Since 2017, Pfizer’s kinase inhibitor Sutent has been approved to help prevent tumors from returning in high-risk kidney cancer patients after surgery. But its efficacy and safety are far from ideal.

Now, Merck & Co. hopes to set a new standard of care with its PD-1 inhibitor Keytruda.